FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject to	STATE
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

MENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MERRIFIELD C ANN					2. Issuer Name and Ticker or Trading Symbol Lyra Therapeutics, Inc. [LYRA]							(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last)	(First)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/30/2023									(give title		specify
C/O LYRA THERAPEUTICS, INC. 480 ARSENAL WAY				4. If a									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
(Street) WATERTOWN MA 02472			Pu	Dula 10hE 1(a) Transportion Indication								Form filed by More than One Reporting Person					
(City)	(State)	(Zip)		-	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											
		Tab	le I - No	n-Deriv	<i>r</i> ative	Sec	curities	s Ac	quired, D	ispos	sed o	f, or Be	neficial	ly Owned	t		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					ay/Year) Exe		ed Date, y/Year	Transaction D Code (Instr. 5)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			Benefici Owned F	es Formally (D) (Following (I) (I	6. Ownership Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	V A	Amount		r Price	Reported Transact (Instr. 3	tion(s)		(Instr. 4)
		7							uired, Dis , options					Owned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Execution	Date,	4. Transac Code (Ir 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		and	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expir Date	ation	Title	Amount or Number of Shares				
Stock Option	\$4.11	06/30/2023			A		20,000		(1)	06/29	/2033	Common Stock	20,000	\$0	20,000	D	

Explanation of Responses:

1. This option vests and becomes exercisable on June 30, 2024, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date.

/s/ Jason Cavalier, Attorney-in-07/05/2023 Fact for C. Ann Merrifield

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.